This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License
Tafasitamab, sold under the brand name Monjuvi, is a medication used in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Tafasitamab may cause serious side effects including infusion related reactions, bone marrow suppression, infections, and harm to an unborn baby. The most common side effects of tafasitamab are low blood cell counts, fatigue, diarrhea, cough, fever, limb swelling, upper respiratory infection, and decreased appetite. Tafasitamab is a humanized Fc-modified cytolytic CD19 antibody.
| Property | Value |
|---|---|
| dbo:abstract |
|
| dbo:alternativeName |
|
| dbo:casNumber |
|
| dbo:drugbank |
|
| dbo:fdaUniiCode |
|
| dbo:kegg |
|
| dbo:wikiPageExternalLink | |
| dbo:wikiPageID |
|
| dbo:wikiPageLength |
|
| dbo:wikiPageRevisionID |
|
| dbo:wikiPageWikiLink | |
| dbp:atcPrefix |
|
| dbp:atcSuffix |
|
| dbp:c |
|
| dbp:casNumber |
|
| dbp:dailymedid |
|
| dbp:drugbank |
|
| dbp:h |
|
| dbp:kegg |
|
| dbp:legalCa |
|
| dbp:legalEu |
|
| dbp:legalUs |
|
| dbp:mabType |
|
| dbp:n |
|
| dbp:o |
|
| dbp:routesOfAdministration | |
| dbp:s |
|
| dbp:source |
|
| dbp:synonyms |
|
| dbp:target | |
| dbp:tradename |
|
| dbp:type |
|
| dbp:unii |
|
| dbp:wikiPageUsesTemplate | |
| dcterms:subject | |
| rdf:type | |
| rdfs:comment |
|
| rdfs:label |
|
| owl:sameAs | |
| prov:wasDerivedFrom | |
| foaf:isPrimaryTopicOf | |
| is dbo:wikiPageRedirects of | |
| is dbo:wikiPageWikiLink of | |
| is foaf:primaryTopic of |